UK access routes, dated and sourced — a second dataset

Posting this under the heading it deserves: UK access routes, dated and sourced — a second dataset Everything below is what sits behind that.

Regional question, dated January 2026, because everything in this category expires.

The position differs between the jurisdictions people usually treat as one, and the differences are not marginal. I have set out what I can verify for my own region from primary sources rather than summaries.

If you can confirm or contradict this for yours, please date the answer.

I read the opening post twice before replying, because I had assumed the opposite.

Waiting times are the most variable and least generalisable thing reported here, and they are worth posting anyway with a region and a date.

The variance between people here is larger than the effect being discussed.

This follows the opening post rather than contradicting it.

Regional variation in NHS: access varies dramatically by region depending on local commissioning decisions and specialist service availability. Postcode determines access risk.

That matches what I was told, which is not the same as knowing it.

Members outside these two jurisdictions reading this thread should note that none of it transfers, including the parts that sound general.

Not the whole picture, but the part of it I can speak to.

Grateful for the specificity. Vague answers to this question are what sent me looking.

Compounding pharmacies: UK allows compounding under specific conditions when a licensed product is unavailable. That is not a front-line option but becomes relevant during shortages.

Cost comparisons should state whether they include the consultation, the device, the needles and the follow-up, because those differ between routes.

Confirming post #8 from a second method, which matters more than confirming it from a second person.

Cross-border arrangements: some people source from other EU countries. Rules on import for personal use are changing post-Brexit. Current status requires checking with UKVI.

Worth saying I have only my own numbers here, and n is small.

MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private prescribing routes exist with materially different access criteria and costs.

Importing for personal use: importing a prescription-only medicine without a prescription is not lawful. Material sold as research-use-only is not a licensed medicine regardless of content.

I would put this at better than even and not much better.

Occupational health screening: some UK occupations require medical checks. Disclosure of weight-loss medication might be relevant to employment screening; understand your obligations.

Where I part company with post #9, and it is a narrow parting.

Date the claim and say whether it is the United Kingdom or Ireland. They are different regulatory jurisdictions and the answer is frequently different.

I have said this before in a thread nobody could find, so it is worth repeating.

Where the compound is supplied with a device, the device and the compound have separate availability positions and the device is more often the constraint.

The uncertainty is in the assumption, not in the calculation.